



Issued: 27 June 2024, Singapore

GSK set to achieve 100% renewable electricity at all manufacturing sites in Singapore from 2025

- Manufacturing operations in Singapore will move from 3% to 100% renewable electricity, generated directly on-site and procured through renewable energy certificates from solar projects
- 10-year energy deal with Sembcorp set to increase GSK's global purchased renewable electricity usage by 9%
- Important step towards GSK's global target of 100% purchased renewable electricity across all sites by end 2025

GSK has today announced it has signed a 10-year energy deal with Sembcorp, covering the electricity demand for all three of GSK's global manufacturing sites in Singapore. This means that from 1 January 2025, all of GSK's manufacturing operations in Singapore will be covered by renewable energy certificates from Sembcorp's solar projects in Singapore and the 3% already being generated by GSK's on-site solar panels.

This deal will facilitate the supply of renewable energy certificates for up to 87,600MWh¹ of electricity annually, equivalent to approximately 36,500MT of CO₂², which is set to increase GSK's global purchased renewable electricity usage by 9%.

GSK's manufacturing facilities in Singapore are critical for the production of innovative medicines and vaccines for HIV, oncology and infectious diseases. This deal is part of GSK's ongoing investment and commitment to Singapore, where GSK has had a presence since 1959 and today employs over 1,500 people. It has invested more than S\$2.5 billion (£1.5 billion) in Singapore to date.

Regis Simard, President, Global Supply Chain, GSK said: "I'm proud that we've been able to sign this deal to transition our manufacturing sites in Singapore to renewable electricity from 2025. We are working to decarbonise our manufacturing facilities globally through purchasing renewable electricity as well as investing in on-site renewable electricity generation. This is an important part of how we are reducing the carbon impact of our medicines and vaccines.

Vickrem Vijayan, Head of Energy Commercial, Singapore, Sembcorp said: "As a leading renewable energy player in Asia, Sembcorp is well-equipped to support its customers to decarbonise through its global renewable energy portfolio and suite of carbon management solutions. We are delighted to be a part of GSK's decarbonisation journey, and look forward to helping more corporates progress towards their sustainability goals."

Healthcare systems globally account for roughly 5% of all emissions, with more than half of these emissions being created in manufacturing supply chains. Renewable electricity deals like this are part of how GSK is working to

¹ Equivalent to 10MW

² Calculated using the latest Grid Emission Factor of 0.417kgCO₂/KWh for calendar year 2022 published by the Energy Market Authority of Singapore



deliver on its ambitious sustainability targets, and to reduce the environmental impact of developing and manufacturing medicines and vaccines.

Transitioning to renewable energy, which will improve air quality, also has important benefits for respiratory and human health.

At a global level, GSK is committed to an 80% reduction in greenhouse gas emissions across all scopes by 2030 and a 90% reduction by 2045, from a 2020 baseline. This includes a commitment as part of the RE100 initiative to 100% purchased renewable electricity by 2025 and 100% renewable electricity (purchased and generated on-site) by 2030. At the end of 2023 (using the last published data), GSK had reached 83% purchased renewable electricity across its operations.

About GSK in Singapore

GSK was the first global healthcare company to establish a presence in Singapore in 1959. For over 60 years, GSK has been an important contributor to the healthcare system and the biopharma manufacturing sector in Singapore. GSK is one of the biggest contributors to Singapore's biomedical sciences industry with investments of more than S\$2.5 billion.

Singapore is the headquarters for our Global General Medicines (GM) business and is also the regional headquarters for our Greater China and Intercontinental (GCI) and Emerging Markets (EM) regions. It houses 3 vital manufacturing sites, comprising two medicines manufacturing sites and a vaccines manufacturing facility. Today GSK employs over 1,500 people in Singapore, every one of whom share our mission to get ahead of disease together. For more information, please visit [Singapore | GSK](#)

About GSK

GSK is a global biopharma company with the ambition and purpose to unite science, technology and talent to get ahead of disease together. For further information, please visit www.gsk.com

For media queries, please contact:

GSK Singapore

Allyanna Anglim allyanna.x.anglim@gsk.com